Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 4/20 | 0.47 |
| ▸ | MCHR1 | Q99705 | 12/20 | 0.45 |
| ▸ | TACR1 | P25103 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4264161 | 0.99 | TACR2 (0.46) | TACR2MCHR1TACR1CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL4259342 | 0.99 | TACR2 (0.46) | TACR2MCHR1TACR1CYP3A4CYP2D6 | |
| SCHEMBL5013601 | 0.86 | MCHR1 (0.50) | TACR2MCHR1TACR1CYP3A4CYP2D6 | |
| SCHEMBL5016489 | 0.86 | TACR2 (0.49) | TACR2MCHR1CYP3A4CYP2D6SLC6A2 | |
| Hydrochloric Acid SCHEMBL4259335 | 0.85 | MCHR1 (0.49) | TACR2MCHR1TACR1CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL4406052 | 0.85 | MCHR1 (0.49) | TACR2MCHR1TACR1CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL4264152 | 0.85 | MCHR1 (0.49) | TACR2MCHR1TACR1CYP3A4CYP2D6 | |
| Hydrochloric Acid SCHEMBL4269274 | 0.85 | TACR2 (0.48) | TACR2MCHR1CYP3A4CYP2D6SLC6A2 | |
| SCHEMBL4258141 | 0.84 | TACR2 (0.53) | TACR2MCHR1TACR1 | |
| SCHEMBL4262378 | 0.82 | SLC6A3 (0.35) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7402581-B2 | Azetidine compounds | ALBIREO AB (SE) | 2008-07-22 | — | — | US | disclosed |
| US-20060172988-A1 | Azetidine compounds | ALBIREO AB (SE) | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060172988-A1 | Azetidine compounds | HRH2, HRH4, HRH1 | TACR2 19/4885MCHR1 698/4885TACR1 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.